Literature DB >> 17924177

Etoposide attenuates zymosan-induced shock in mice.

M Remichkova1, M Yordanov, P Dimitrova.   

Abstract

Zymosan-induced generalized inflammation is a convenient model to study the process of acute and chronic inflammatory processes resulting in multiple organ dysfunction syndrome. Macrophages as a source of many pro-inflammatory mediators are the major players in shock and further organ failure. Etoposide is a cytostatic drug known to reduce macrophages and monocytes in blood circulation. In the present study we have investigated whether the ability of etoposide to diminish macrophage number would have an impact on the course of zymosan-induced shock. The drug injected at a dose of 10 mg/kg 1 day before zymosan, significantly reduced the mortality and decreased the organ toxicity in Balb/c mice. Simultaneously, an inhibition of TNF-alpha production by alveolar and peritoneal macrophages was observed. Etoposide administered into mice with severe combined immunodeficiency (SCID) did not change the survival rate and had a little influence on organ toxicity. Our findings suggest that the beneficial action of etoposide might be attributed to the reduction of macrophages and alteration of their functions. Its effect depends on the presence of functional T and B lymphocytes. The results deserve further investigation of etoposide as a perspective therapeutic tool for inhibiting the excessive inflammatory response and to be helpful for revealing mechanisms of shock development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924177     DOI: 10.1007/s10753-007-9049-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  27 in total

Review 1.  A question of balance.

Authors:  S Nelson
Journal:  Am J Respir Crit Care Med       Date:  1999-05       Impact factor: 21.405

2.  Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice.

Authors:  Oliver Goldmann; Gursharan S Chhatwal; Eva Medina
Journal:  J Infect Dis       Date:  2005-03-04       Impact factor: 5.226

3.  Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies.

Authors:  Guangxun Meng; Alina Grabiec; Mark Rutz; Jochen Metzger; Peter B Luppa; Hermann Wagner; Stefan Bauer; Carsten J Kirschning
Journal:  Immunol Lett       Date:  2004-12-08       Impact factor: 3.685

Review 4.  Sepsis and cytokines: current status.

Authors:  T S Blackwell; J W Christman
Journal:  Br J Anaesth       Date:  1996-07       Impact factor: 9.166

Review 5.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

6.  Macrophage recognition of zymosan particles.

Authors:  David M Underhill
Journal:  J Endotoxin Res       Date:  2003

7.  Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase.

Authors:  Thomas J H Volman; R Jan A Goris; Michel van der Jagt; Fons A J van de Loo; Thijs Hendriks
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

8.  Impact of topoisomerase II inhibition on cytokine and chemokine production.

Authors:  M Verdrengh; A Tarkowski
Journal:  Inflamm Res       Date:  2003-04       Impact factor: 4.575

Review 9.  Etoposide. Current and future status.

Authors:  J Aisner; E J Lee
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

10.  Influence of etoposide and cyclophosphamide on the efficacy of cloxacillin and erythromycin in an experimental staphylococcal infection.

Authors:  W Calame; R van der Waals; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

View more
  5 in total

1.  The skeletal impact of the chemotherapeutic agent etoposide.

Authors:  A J Koh; B P Sinder; P Entezami; L Nilsson; L K McCauley
Journal:  Osteoporos Int       Date:  2017-04-20       Impact factor: 4.507

Review 2.  Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.

Authors:  Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 3.  Novel insights for systemic inflammation in sepsis and hemorrhage.

Authors:  Bolin Cai; Edwin A Deitch; Luis Ulloa
Journal:  Mediators Inflamm       Date:  2010-06-08       Impact factor: 4.711

4.  Wedelolactone from Vietnamese Eclipta prostrata (L) L. Protected Zymosan-induced shock in Mice.

Authors:  Trinh Tat Cuong; Giang Huy Diem; Tran Trung Doan; Nguyen Quang Huy; Nguyen Phuong; Hoang The Hung
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

5.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.